Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression

Caroline Oberholzer, Andreas Oberholzer, Sven K. Tschoeke, Rebecca M. Minter, Frances R. Bahjat, Drake LaFace, Beth Hutchins, Lyle L. Moldawer

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Adenovirus-based gene therapy offers a unique opportunity to target gene expression to the liver by systemic delivery. However, systemic administration of a first generation adenoviral construct elicits an inflammatory response leading to TNF-α-dependent liver injury. The aim of this study was to evaluate whether the systemic administration of recombinant adenovirus exacerbates a subsequent TNF-α-dependent liver injury induced by D-galactosamine and lipopolysaccharide. Surprisingly, low-dose adenovirus administration (105 particles) protects, while high-dose adenovirus (1010 particles) is associated with an exaggerated hepatic inflammatory response from a subsequent D-galactosamine and lipopolysaccharide challenge. This exacerbation is TNF-α dependent, since treatment with a TNF inhibitor fully protects against the liver injury. Moreover, intravenous administration of an adenoviral construct expressing the anti-inflammatory protein interleukin-10 reduces TNF-α appearance and attenuates the increased hepatocyte injury. Taken together, this report demonstrates potential additive effects of TNF-α responses induced by adenovirus and other inflammatory signals, and suggests that the response can be mitigated by relative adenovirus particle dose or by inhibitors, such as TNF-binding protein or interleukin 10.

Original languageEnglish (US)
Pages (from-to)393-401
Number of pages9
JournalJournal of Endotoxin Research
Volume10
Issue number6
DOIs
StatePublished - Dec 22 2004

Fingerprint

Adenoviridae
Liver
Interleukin-10
Modulation
Galactosamine
Wounds and Injuries
Lipopolysaccharides
Gene therapy
Gene expression
Carrier Proteins
Anti-Inflammatory Agents
Intravenous Administration
Genetic Therapy
Hepatocytes
Gene Expression
Proteins

Keywords

  • Apoptosis
  • Cytokine
  • Gene therapy
  • Inflammation
  • Lipopolysaccharide

ASJC Scopus subject areas

  • Microbiology
  • Immunology
  • Toxicology

Cite this

Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression. / Oberholzer, Caroline; Oberholzer, Andreas; Tschoeke, Sven K.; Minter, Rebecca M.; Bahjat, Frances R.; LaFace, Drake; Hutchins, Beth; Moldawer, Lyle L.

In: Journal of Endotoxin Research, Vol. 10, No. 6, 22.12.2004, p. 393-401.

Research output: Contribution to journalArticle

Oberholzer, C, Oberholzer, A, Tschoeke, SK, Minter, RM, Bahjat, FR, LaFace, D, Hutchins, B & Moldawer, LL 2004, 'Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression', Journal of Endotoxin Research, vol. 10, no. 6, pp. 393-401. https://doi.org/10.1179/096805104225005832
Oberholzer, Caroline ; Oberholzer, Andreas ; Tschoeke, Sven K. ; Minter, Rebecca M. ; Bahjat, Frances R. ; LaFace, Drake ; Hutchins, Beth ; Moldawer, Lyle L. / Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression. In: Journal of Endotoxin Research. 2004 ; Vol. 10, No. 6. pp. 393-401.
@article{da878a33793a41deab0391f8af1309d2,
title = "Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression",
abstract = "Adenovirus-based gene therapy offers a unique opportunity to target gene expression to the liver by systemic delivery. However, systemic administration of a first generation adenoviral construct elicits an inflammatory response leading to TNF-α-dependent liver injury. The aim of this study was to evaluate whether the systemic administration of recombinant adenovirus exacerbates a subsequent TNF-α-dependent liver injury induced by D-galactosamine and lipopolysaccharide. Surprisingly, low-dose adenovirus administration (105 particles) protects, while high-dose adenovirus (1010 particles) is associated with an exaggerated hepatic inflammatory response from a subsequent D-galactosamine and lipopolysaccharide challenge. This exacerbation is TNF-α dependent, since treatment with a TNF inhibitor fully protects against the liver injury. Moreover, intravenous administration of an adenoviral construct expressing the anti-inflammatory protein interleukin-10 reduces TNF-α appearance and attenuates the increased hepatocyte injury. Taken together, this report demonstrates potential additive effects of TNF-α responses induced by adenovirus and other inflammatory signals, and suggests that the response can be mitigated by relative adenovirus particle dose or by inhibitors, such as TNF-binding protein or interleukin 10.",
keywords = "Apoptosis, Cytokine, Gene therapy, Inflammation, Lipopolysaccharide",
author = "Caroline Oberholzer and Andreas Oberholzer and Tschoeke, {Sven K.} and Minter, {Rebecca M.} and Bahjat, {Frances R.} and Drake LaFace and Beth Hutchins and Moldawer, {Lyle L.}",
year = "2004",
month = "12",
day = "22",
doi = "10.1179/096805104225005832",
language = "English (US)",
volume = "10",
pages = "393--401",
journal = "Innate Immunity",
issn = "1753-4259",
publisher = "SAGE Publications Ltd",
number = "6",

}

TY - JOUR

T1 - Influence of recombinant adenovirus on liver injury in endotoxicosis and its modulation by IL-10 expression

AU - Oberholzer, Caroline

AU - Oberholzer, Andreas

AU - Tschoeke, Sven K.

AU - Minter, Rebecca M.

AU - Bahjat, Frances R.

AU - LaFace, Drake

AU - Hutchins, Beth

AU - Moldawer, Lyle L.

PY - 2004/12/22

Y1 - 2004/12/22

N2 - Adenovirus-based gene therapy offers a unique opportunity to target gene expression to the liver by systemic delivery. However, systemic administration of a first generation adenoviral construct elicits an inflammatory response leading to TNF-α-dependent liver injury. The aim of this study was to evaluate whether the systemic administration of recombinant adenovirus exacerbates a subsequent TNF-α-dependent liver injury induced by D-galactosamine and lipopolysaccharide. Surprisingly, low-dose adenovirus administration (105 particles) protects, while high-dose adenovirus (1010 particles) is associated with an exaggerated hepatic inflammatory response from a subsequent D-galactosamine and lipopolysaccharide challenge. This exacerbation is TNF-α dependent, since treatment with a TNF inhibitor fully protects against the liver injury. Moreover, intravenous administration of an adenoviral construct expressing the anti-inflammatory protein interleukin-10 reduces TNF-α appearance and attenuates the increased hepatocyte injury. Taken together, this report demonstrates potential additive effects of TNF-α responses induced by adenovirus and other inflammatory signals, and suggests that the response can be mitigated by relative adenovirus particle dose or by inhibitors, such as TNF-binding protein or interleukin 10.

AB - Adenovirus-based gene therapy offers a unique opportunity to target gene expression to the liver by systemic delivery. However, systemic administration of a first generation adenoviral construct elicits an inflammatory response leading to TNF-α-dependent liver injury. The aim of this study was to evaluate whether the systemic administration of recombinant adenovirus exacerbates a subsequent TNF-α-dependent liver injury induced by D-galactosamine and lipopolysaccharide. Surprisingly, low-dose adenovirus administration (105 particles) protects, while high-dose adenovirus (1010 particles) is associated with an exaggerated hepatic inflammatory response from a subsequent D-galactosamine and lipopolysaccharide challenge. This exacerbation is TNF-α dependent, since treatment with a TNF inhibitor fully protects against the liver injury. Moreover, intravenous administration of an adenoviral construct expressing the anti-inflammatory protein interleukin-10 reduces TNF-α appearance and attenuates the increased hepatocyte injury. Taken together, this report demonstrates potential additive effects of TNF-α responses induced by adenovirus and other inflammatory signals, and suggests that the response can be mitigated by relative adenovirus particle dose or by inhibitors, such as TNF-binding protein or interleukin 10.

KW - Apoptosis

KW - Cytokine

KW - Gene therapy

KW - Inflammation

KW - Lipopolysaccharide

UR - http://www.scopus.com/inward/record.url?scp=10244263422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10244263422&partnerID=8YFLogxK

U2 - 10.1179/096805104225005832

DO - 10.1179/096805104225005832

M3 - Article

VL - 10

SP - 393

EP - 401

JO - Innate Immunity

JF - Innate Immunity

SN - 1753-4259

IS - 6

ER -